A- A A+

Schweiz. Diamorphinsubstitution: Stellungnahme des BAG zu HeGeBe unter dem Eindruck des Corona-Virus

Das BAG nimmt Stellung (pdf, 2S.) zu den eingegangenen Fragen bezüglich der aktuellen Herausforderungen der HeGeBe Institutionen im Zusammenhang mit COVID-19. (Bundesamt für Gesundheit, Bern, 13.03.2020)

https://fachverbandsucht.ch/download/898/COVID-19_Pandemie_und_Mitgaben_in_HeGeBe_Antwort_vom_BAG_final.pdf

Norwegen. Information from the Norwegian Centre for Addiction Research (SERAF), University of Oslo, Norway, about special measures for vulnerable groups with substance use disorders (SUD) during the Coronavirus epidemic

UIO – Institut of Clinical Medicie, Faculty of Medicine, Prof. Dr. med. Thomas Clausen, Norwegen, 15.03.2020)

https://www.med.uio.no/klinmed/english/research/centres/seraf/news-and-events/news/2020/information-seraf-coronavirus.html

Australien. Guidance for AOD Services about COVID-19

New South Wales Government, Health, wird laufend aktualisiert

https://www.health.nsw.gov.au/aod/Pages/covid19-aod-services-response.aspx

New York. New York State Office of Addiction Services and Supports – Opioid Treatment Programmes (OTP)  and Covid-19.

(OASAS - New York State Office of Addiction Services and Supports, 10.03.2020.)

https://oasas.ny.gov/system/files/documents/2020/03/3-10-2020-covid-19-guidance-for-otp.pdf

Wien. PatientInnen-Information zur Heimquarantäne und Medikamentenversorgung

(Suchthilfe Wien, Österreich, 24.03.2020)

240320 Wien Info_Aufsuchende Notversorgung_SHW_PatientIn_ZuweiserInnen

Wien. Prozess der Sicherstellung der Substitutionsmedikation bzw. Psychopharmaka bei PatientInnen in Heimquarantäne

(Suchthilfe Wien, Österreich, 24.03.2020 )

240320 Wien Grafik Ablauf COVID-19 Substitution-Psychopharmaka Heimquarantäne.pdf

Österreich/Wien. COVID-19 Ablauf Versorgung von PatientInnen mit Substitutions- bzw. Psychopharmakologischer Medikation zur Entlastung des Gesundheitssystems

(Suchthilfe Wien, Österreich, 24.03.2020 )

240320_Wien. Ablauf_COVID19-Substitution-Psychopharmaka

Opioidagonistentherapie (OAT) und COVID-19 Pandemie: Empfehlungen der Schweizerischen Gesellschaft für Suchtmedizin (SSAM) 

Mit der zunehmenden Ausbreitung des COVID-19 stehen wir in unseren Praxen und Institutionen bezüglich der Behandlung von Personen mit Opioidabhängigkeit vor gros- sen Herausforderungen. 

Die in diesem Dokument zusammengefassten Empfehlungen stellen den aktuellen Stand der Erkenntnisse dar und werden laufend auf unserer Homepage aktualisiert. Die spezifischen kantonalen Richtlinien sind unabhängig davon zu berücksichtigen. Die entsprechenden Links finden Sie unter Praxis Suchtmedizin Schweiz oder In- fodrog. (SSAM – Schweizerische Gesellschaft für Suchtmedizin, 24.03.2020)

https://www.ssam.ch/cmf/site/assets/files/1171/empfehlungen_der_ssam_fur_oat_und_covid-19_pandemie.pdf

USA. Use of Telemedicine While Providing Medication Assisted Treatment (MAT) 

(US Department of Justice, Drug Enforcement Administration, Diversion Control Division, 15.05.2018)

https://www.deadiversion.usdoj.gov/mtgs/pract_awareness/resources/Telemedicine_MAT.pdf

China. Leitlinie zum Umgang mit der Coronavirus-Epidemie (dt. Übersetzung)

Version 7, China, 16.03.2020

Leitlinie_zum_Umgang_mit_der__Coronavirus_Epidemie_V7

AATOD Guidance to OTPs in Response to the Coronavirus (COVID-19) 

Maintaining Adequate Supplies of Medications and Other Vital Materials
OTPs should determine their medication management needs in order to ensure they have the proper inventory needed to treat patients effectively as more take-home medication will be required, especially if the program falls within a quarantine zone. Inventory also includes medical supplies and equipment that the programs will need to function and effectively treat patients. Please keep in mind that this is a rapidly changing event and programs need to be as prepared as possible to deal with such ongoing challenges. (AATOD – American Association fort he Treatment of Opioid Dependence, 20.03.2020)

http://www.aatod.org/advocacy/policy-statements/covid-19-aatods-guidance-for-otps

Schottland. Guidance on Contingency Planning for People who use Drugs and COVID-19 (v1.0) 

Guidance has been produced on contingency planning for people who use drugs and COVID-19 and has been shared with all Alcohol and Drug Partnerships and all drug services in Scotland.

This Guidance has been produced by Scottish Drug Forum and partners including the Sexual Health and BBV Prevention Leads Group with support from Scottish Government. The intention of the Guidance is to support local areas and services in their contingency planning for COVID-19 in relation to people who use drugs and particularly the provision of opiate substitution treatment and injecting equipment provision. (SDF – Scottish Drugs Forum, 19.03.2020)

https://mcusercontent.com/e11f8fc83cbbb714881d3030b/files/a7e79d4d-4e3d-458a-b54c-e0d82ca34877/Guidelines_on_contingency_planning_for_people_who_use_drugs_and_COVID_19_Version_1.pdf

Germany. Information on opioid substitution and Sars-CoV-2/Covid-19 - Advice for physicians

The coronavirus Sars-CoV-2 has reached the first substitution practices and outpatient clinics in Germany. It is now a matter of a pragmatic balancing between securing the supply and ensuring the protection against infection while taking into account the control  of narcotics.

In comparison with other treatment centres and practices, there are hardly any alternative distribution points and treatment centres available when substitution practices are closed.  Therefore changes in the distribution and prescription practice are recommended. (Conference of the Chairmen of Quality Assurance Commissions of the Associations of Statutory Health Insurance Physicians in Germany, 2020 March 16th)

Germany. Information on opioid substitution and Sars-CoV-2/Covid-19 - Advice for physicians

USA. SAMHSA provides COVID-19 guidance for opioid treatment programs. 

(…) Disaster plans shall not include any blanket exceptions for clinic closure and/or take- home medication for all patients to include patients who do not qualify for take- home/unsupervised use of opioid pharmacotherapies. Appropriate alternatives compliant with state and federal guidelines for dosing should be arranged for patients who are not eligible for take-home medication. 

SAMHSA will consider approving COVID -19 exceptions to permit dispensing of take- home opioid pharmacotherapy for up to 14 days for those with exposure to COVID-19 or symptomatic for infection when documented by the patient’s healthcare provider. SAMHSA DPT will only consider exception renewals for up to 14 days that are medically indicated and requested by the individual’s healthcare provider. Every exception request for up to 14 days of opioid pharmacotherapy and related to COVID-19 exposure or infection must be presented to the SOTA who will be required to verify that the exception is necessary. (The Substance Abuse and Mental Health Services Administration (SAMHSA), Division of Pharmacologic Therapies (DPT), Center for Substance Abuse Treatment (CSAT), USA, 13.03.2020)

https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines/covid-19-guidance-otp